Boehringer Ingelheim has put a hold on its Phase I work with a BACE inhibitor for Alzheimer’s, marking the latest in a series of missteps for this category of therapeutics, which has emerged as one of the key arenas in the field.

…read more

Source: Another BACE inhibitor trips up as Boehringer halts Alzheimer’s study


0 No comments